Current and former US Food and Drug Administration officials are expressing broad agreement that COVID-19 will likely be a prod to the wider-ranging acceptance of digital health information from clinical trials.
The practical difficulties of collecting information at specific sites during the mobility restriction of the SARS-CoV2 pandemic are acting as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?